Improving the global reporting of multiple myeloma: a focus on low-income and middle-income countries
Cette étude présente une estimation, au niveau mondial, de l'incidence du myélome multiple pour l'année 2020 et de la mortalité spécifique
The findings reported by Junjie Huang and colleagues, published in The Lancet Haematology, elaborate on the recent trends in the epidemiology of multiple myeloma through several global cancer registries, emphasising the contribution of modifiable risk factors, namely overweight and physical inactivity, towards the development of multiple myeloma. The age-standardised multiple myeloma incidence was 1·78 (95% UI 1·69–1·87) per 100 000 people globally and mortality was 1·14 (95% UI 1·07–1·21) per 100 000 people globally in 2020. Higher multiple myeloma incidence and mortality were reported in high-income countries, which had higher human development index, gross domestics product, prevalence of physical inactivity, overweight, obesity, and diabetes. This analysis highlights the worldwide heterogeneity of the incidence and mortality from multiple myeloma. The highest increase in men older than 50 years was in Germany (average annual percentage change [AAPC] 6·71 [95% CI 0·75–13·02]; p=0·027) and the highest decrease was reported in women aged 50 years or older from the Faroe Islands (21·01 [2·15–43·34]; p=0·032).
The Lancet Haematology , commentaire, 2021